These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 23973637)

  • 21. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: the role of NF-κB and PPAR-γ.
    Alves ÉAR; de Miranda MG; Borges TK; Magalhães KG; Muniz-Junqueira MI
    Int Immunopharmacol; 2015 Feb; 24(2):314-324. PubMed ID: 25545854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
    Su CT; Ling WL; Lua WH; Haw YX; Gan SK
    BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.
    Wu X; Sun L; Zha W; Studer E; Gurley E; Chen L; Wang X; Hylemon PB; Pandak WM; Sanyal AJ; Zhang L; Wang G; Chen J; Wang JY; Zhou H
    Gastroenterology; 2010 Jan; 138(1):197-209. PubMed ID: 19732776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
    Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
    BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Sayer JM; Louis JM
    Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
    Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
    HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
    Jose S; Nelson M; Phillips A; Chadwick D; Trevelion R; Jones R; Williams DI; Hamzah L; Sabin CA; Post FA;
    AIDS; 2017 Feb; 31(4):485-492. PubMed ID: 28121667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
    Arathoon E; Schneider S; Baraldi E; Lim PL; Opravil M; Van De Casteele T; Lavreys L
    Int J STD AIDS; 2013 Jan; 24(1):12-7. PubMed ID: 23440570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High variability of plasma drug concentrations in dual protease inhibitor regimens.
    Guiard-Schmid JB; Poirier JM; Meynard JL; Bonnard P; Gbadoe AH; Amiel C; Calligaris F; Abraham B; Pialoux G; Girard PM; Jaillon P; Rozenbaum W
    Antimicrob Agents Chemother; 2003 Mar; 47(3):986-90. PubMed ID: 12604531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
    Jain RG; Lenhard JM
    J Biol Chem; 2002 May; 277(22):19247-50. PubMed ID: 11937496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
    Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
    Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes.
    Zha BS; Wan X; Zhang X; Zha W; Zhou J; Wabitsch M; Wang G; Lyall V; Hylemon PB; Zhou H
    PLoS One; 2013; 8(3):e59514. PubMed ID: 23533630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
    AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
    Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
    Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.